1
|
Hood G, Laufer-Amorim R, Fonseca-Alves CE
and Palmieri C: Overexpression of ephrin A3 receptor in canine
prostatic carcinoma. J Comp Pathol. 154:180–185. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Xi HQ, Wu XS, Wei B and Chen L: Aberrant
expression of EphA3 in gastric carcinoma: Correlation with tumor
angiogenesis and survival. J Gastroenterol. 47:785–794. 2012.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Nasri B, Inokuchi M, Ishikawa T, Uetake H,
Takagi Y, Otsuki S, Kojima K and Kawano T: High expression of EphA3
(erythropoietin-producing hepatocellular A3) in gastric cancer is
associated with metastasis and poor survival. BMC Clin Pathol.
17:82017. View Article : Google Scholar : PubMed/NCBI
|
4
|
Tímár J, Mészáros L, Ladányi A, Puskás LG
and Rásó E: Melanoma genomics reveals signatures of sensitivity to
bio- and targeted therapies. Cell Immunol. 244:154–157. 2006.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Caivano A, La Rocca F, Laurenzana I,
Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L,
Villani O, et al: Epha3 acts as proangiogenic factor in multiple
myeloma. Oncotarget. 8:34298–34309. 2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
La Rocca F, Airoldi I, Di Carlo E, Marotta
P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K,
et al: EphA3 targeting reduces in vitro adhesion and invasion and
in vivo growth and angiogenesis of multiple myeloma cells. Cell
Oncol. 40:483–496. 2017. View Article : Google Scholar
|
7
|
Lu CY, Yang ZX, Zhou L, Huang ZZ, Zhang
HT, Li J, Tao KS and Xie BZ: High levels of EphA3 expression are
associated with high invasive capacity and poor overall survival in
hepatocellular carcinoma. Oncol Rep. 30:2179–2186. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Day BW, Stringer BW, Al-Ejeh F, Ting MJ,
Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C,
et al: EphA3 maintains tumorigenicity and is a therapeutic target
in glioblastoma multiforme. Cancer Cell. 23:238–248. 2013.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Li M, Yang C, Liu X, Yuan L, Zhang F, Wang
M, Miao D, Gu X, Jiang S, Cui B, et al: EphA3 promotes malignant
transformation of colorectal epithelial cells by upregulating
oncogenic pathways. Cancer Lett. 383:195–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Brantley DM, Cheng N, Thompson EJ, Lin Q,
Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D,
et al: Soluble Eph A receptors inhibit tumor angiogenesis and
progression in vivo. Oncogene. 21:7011–7026. 2002. View Article : Google Scholar : PubMed/NCBI
|
11
|
Swords RT, Greenberg PL, Wei AH, Durrant
S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G,
Gratzinger D, et al: KB004, a first in class monoclonal antibody
targeting the receptor tyrosine kinase EphA3, in patients with
advanced hematologic malignancies: Results from a phase 1 study.
Leuk Res. 50:123–131. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ferluga S, Tomé CM, Herpai DM, D'Agostino
R and Debinski W: Simultaneous targeting of Eph receptors in
glioblastoma. Oncotarget. 7:59860–59876. 2016. View Article : Google Scholar : PubMed/NCBI
|
13
|
Charmsaz S, Al-Ejeh F, Yeadon TM, Miller
KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou
C, et al: EphA3 as a target for antibody immunotherapy in acute
lymphoblastic leukemia. Leukemia. 31:1779–1787. 2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Janes PW, Slape CI, Farnsworth RH,
Atapattu L, Scott AM and Vail ME: EphA3 biology and cancer. Growth
Factors. 32:176–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Lodola A, Giorgio C, Incerti M, Zanotti I
and Tognolini M: Targeting Eph/ephrin system in cancer therapy. Eur
J Med Chem. 142:152–162. 2017. View Article : Google Scholar : PubMed/NCBI
|
16
|
Herath NI, Spanevello MD, Doecke JD, Smith
FM, Pouponnot C and Boyd AW: Complex expression patterns of Eph
receptor tyrosine kinases and their ephrin ligands in colorectal
carcinogenesis. Eur J Cancer. 48:753–762. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Xi HQ and Zhao P: Clinicopathological
significance and prognostic value of EphA3 and CD133 expression in
colorectal carcinoma. J Clin Pathol. 64:498–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Andretta E, Cartón-García F,
Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya
I, Bazzocco S, Bilic J, Rodrigues P, Nieto R, et al: Investigation
of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.
Sci Rep. 7:415762017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Vecchi M, Confalonieri S, Nuciforo P,
Viganò MA, Capra M, Bianchi M, Nicosia D, Bianchi F, Galimberti V,
Viale G, et al: Breast cancer metastases are molecularly distinct
from their primary tumors. Oncogene. 27:2148–2158. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Clifford N, Smith LM, Powell J,
Gattenlöhner S, Marx A and O'Connor R: The EphA3 receptor is
expressed in a subset of rhabdomyosarcoma cell lines and suppresses
cell adhesion and migration. J Cell Biochem. 105:1250–1259. 2008.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Chiappalupi S, Riuzzi F, Fulle S, Donato R
and Sorci G: Defective RAGE activity in embryonal rhabdomyosarcoma
cells results in high PAX7 levels that sustain migration and
invasiveness. Carcinogenesis. 35:2382–2392. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhuang G, Song W, Amato K, Hwang Y, Lee K,
Boothby M, Ye F, Guo Y, Shyr Y, Lin L, et al: Effects of
cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer
Inst. 104:1182–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Peng J, Wang Q, Liu H, Ye M, Wu X and Guo
L: EPHA3 regulates the multidrug resistance of small cell lung
cancer via the PI3K/BMX/STAT3 signaling pathway. Tumour Biol.
37:11959–11971. 2016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Hafner C, Schmitz G, Meyer S, Bataille F,
Hau P, Langmann T, Dietmaier W, Landthaler M and Vogt T:
Differential gene expression of Eph receptors and ephrins in benign
human tissues and cancers. Clin Chem. 50:490–499. 2004. View Article : Google Scholar : PubMed/NCBI
|
25
|
Vail ME, Murone C, Tan A, Hii L, Abebe D,
Janes PW, Lee FT, Baer M, Palath V, Bebbington C, et al: Targeting
EphA3 inhibits cancer growth by disrupting the tumor stromal
microenvironment. Cancer Res. 74:4470–4481. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Fox BP, Tabone CJ and Kandpal RP:
Potential clinical relevance of Eph receptors and ephrin ligands
expressed in prostate carcinoma cell lines. Biochem Biophys Res
Commun. 342:1263–1272. 2006. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wu R, Wang H, Wang J, Wang P, Huang F, Xie
B, Zhao Y, Li S and Zhou J: EphA3, induced by PC-1/PrLZ,
contributes to the malignant progression of prostate cancer. Oncol
Rep. 32:2657–2665. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
World Health Organization: Global battle
against cancer won't be won with treatment alone-effective
prevention measures urgently needed to prevent cancer crisis. Cent
Eur J Public Health. 22:23–28. 2014.PubMed/NCBI
|
29
|
Roviello G, Sigala S, Sandhu S, Bonetta A,
Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB and
Generali D: Role of the novel generation of androgen receptor
pathway targeted agents in the management of castration-resistant
prostate cancer: A literature based meta-analysis of randomized
trials. Eur J Cancer. 61:111–121. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Komura K, Jeong SH, Hinohara K, Qu F, Wang
X, Hiraki M, Azuma H, Lee GS, Kantoff PW and Sweeney CJ: Resistance
to docetaxel in prostate cancer is associated with androgen
receptor activation and loss of KDM5D expression. Proc Natl Acad
Sci USA. 113:6259–6264. 2016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Geynisman DM, Plimack ER and Zibelman M:
Second-generation androgen receptor-targeted therapies in
nonmetastatic castration-resistant prostate cancer: Effective early
intervention or intervening too early? Eur Urol. 70:971–973. 2016.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Juang HH, Hsieh ML and Tsui KH:
Testosterone modulates mitochondrial aconitase in the full-length
human androgen receptor-transfected PC-3 prostatic carcinoma cells.
J Mol Endocrinol. 33:121–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
33
|
Zhao H, Zhu C, Qin C, Tao T, Li J, Cheng
G, Li P, Cao Q, Meng X, Ju X, et al: Fenofibrate down-regulates the
expressions of androgen receptor (AR) and AR target genes and
induces oxidative stress in the prostate cancer cell line LNCaP.
Biochem Biophys Res Commun. 432:320–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Lee WS, Kwon J, Yun DH, Lee YN, Woo EY,
Park MJ, Lee JS, Han YH and Bae IH: Specificity protein 1
expression contributes to Bcl-w-induced aggressiveness in
glioblastoma multiforme. Mol Cells. 37:17–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Simon P: Q-Gene: Processing quantitative
real-time RT-PCR data. Bioinformatics. 19:1439–1440. 2003.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Dottori M, Down M, Hüttmann A, Fitzpatrick
DR and Boyd AW: Cloning and characterization of EphA3 (Hek) gene
promoter: DNA methylation regulates expression in hematopoietic
tumor cells. Blood. 94:2477–2486. 1999.PubMed/NCBI
|
37
|
Liao X, Tang S, Thrasher JB, Griebling TL
and Li B: Small-interfering RNA-induced androgen receptor silencing
leads to apoptotic cell death in prostate cancer. Mol Cancer Ther.
4:505–515. 2005. View Article : Google Scholar : PubMed/NCBI
|
38
|
Boyd AW, Ward LD, Wicks IP, Simpson RJ,
Salvaris E, Wilks A, Welch K, Loudovaris M, Rockman S and Busmanis
I: Isolation and characterization of a novel receptor-type protein
tyrosine kinase (hek) from a human pre-B cell line. J Biol
Chem. 267:3262–3267. 1992.PubMed/NCBI
|
39
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Matsumoto T, Sakari M, Okada M, Yokoyama
A, Takahashi S, Kouzmenko A and Kato S: The androgen receptor in
health and disease. Annu Rev Physiol. 75:201–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
41
|
Vizcaíno C, Mansilla S and Portugal J: Sp1
transcription factor: A long-standing target in cancer
chemotherapy. Pharmacol Ther. 152:111–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
42
|
Beishline K and Azizkhan-Clifford J: Sp1
and the ‘hallmarks of cancer’. FEBS J. 282:224–258. 2015.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Safe S, Imanirad P, Sreevalsan S, Nair V
and Jutooru I: Transcription factor Sp1, also known as specificity
protein 1 as a therapeutic target. Expert Opin Ther Targets.
18:759–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
44
|
Sankpal UT, Goodison S, Abdelrahim M and
Basha R: Targeting Sp1 transcription factors in prostate cancer
therapy. Med Chem. 7:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
45
|
Eisermann K, Broderick CJ, Bazarov A,
Moazam MM and Fraizer GC: Androgen up-regulates vascular
endothelial growth factor expression in prostate cancer cells via
an Sp1 binding site. Mol Cancer. 12:72013. View Article : Google Scholar : PubMed/NCBI
|
46
|
Lu S, Jenster G and Epner DE: Androgen
induction of cyclin-dependent kinase inhibitor p21 gene: Role of
androgen receptor and transcription factor Sp1 complex. Mol
Endocrinol. 14:753–760. 2000. View Article : Google Scholar : PubMed/NCBI
|
47
|
Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia
L, Lee LF, Pretlow TG and Kung HJ: Characterization of a novel
androgen receptor mutation in a relapsed CWR22 prostate cancer
xenograft and cell line. Cancer Res. 62:6606–6614. 2002.PubMed/NCBI
|
48
|
Attardi BJ, Burgenson J, Hild SA and Reel
JR: Steroid hormonal regulation of growth, prostate specific
antigen secretion, and transcription mediated by the mutated
androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol
Cell Endocrinol. 222:121–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
49
|
Li Y, Hwang TH, Oseth LA, Hauge A,
Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA and
Dehm SM: AR intragenic deletions linked to androgen receptor splice
variant expression and activity in models of prostate cancer
progression. Oncogene. 31:4759–4767. 2012. View Article : Google Scholar : PubMed/NCBI
|
50
|
Singh AP, Bafna S, Chaudhary K,
Venkatraman G, Smith L, Eudy JD, Johansson SL, Lin MF and Batra SK:
Genome-wide expression profiling reveals transcriptomic variation
and perturbed gene networks in androgen-dependent and
androgen-independent prostate cancer cells. Cancer Lett. 259:28–38.
2008. View Article : Google Scholar : PubMed/NCBI
|
51
|
Yuan TC, Veeramani S and Lin MF:
Neuroendocrine-like prostate cancer cells: Neuroendocrine
transdifferentiation of prostate adenocarcinoma cells. Endocr Relat
Cancer. 14:531–547. 2007. View Article : Google Scholar : PubMed/NCBI
|
52
|
Bao BY, Chuang BF, Wang Q, Sartor O, Balk
SP, Brown M, Kantoff PW and Lee GS: Androgen receptor mediates the
expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.
Prostate. 68:839–848. 2008. View Article : Google Scholar : PubMed/NCBI
|
53
|
Wang Y, Wang Y, Liu Q, Xu G, Mao F, Qin T,
Teng H, Cai W, Yu P, Cai T, et al: Comparative RNA-seq analysis
reveals potential mechanisms mediating the conversion to androgen
independence in an LNCaP progression cell model. Cancer Lett.
342:130–138. 2014. View Article : Google Scholar : PubMed/NCBI
|
54
|
Chen CD and Sawyers CL: NF-kappa B
activates prostate-specific antigen expression and is upregulated
in androgen-independent prostate cancer. Mol Cell Biol.
22:2862–2870. 2002. View Article : Google Scholar : PubMed/NCBI
|